Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids
Status:
Withdrawn
Trial end date:
2019-12-25
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to show superiority of vilaprisan in the treatment of
heavy menstrual bleeding (HMB) in subjects with uterine fibroids compared to placebo.The
secondary objectives of this study are to additionally evaluate the efficacy and safety of
vilaprisan in subjects with uterine fibroids.